AKTS · Aktis Oncology, Inc.

The thesis

Aktis Oncology is a pre-data radiopharmaceutical developer with cash into 2029, and its shares keep falling ahead of the first clinical readout. The adjusted daily close was $16.42 on 21 October 2026, with a three-month change of -31.3% and a 14-day Relative Strength Index (RSI) of 32.3. Preliminary Phase 1b NECTINIUM-2 data, guided for the first quarter of 2027, settles the case.

The narrative is maturing: five analyst firms have initiated or reiterated targets of $35 to $40 since June, Aktis presented at the Morgan Stanley conference on 16 September 2026, and Wedbush reiterated Outperform with a $35 target on 2 October 2026. The price has fallen from $17.74 on 8 October 2026 to $16.42 on 21 October 2026 with no new company announcement in that span.

Bullish and bearish views on Aktis Oncology, Inc.

The bull case on Aktis Oncology, Inc. (AKTS), in brief: Cash covers the guided development window. The bear case: The $22 recovery level failed.

Bull case

• Cash covers the guided development window. Aktis reported $517.3 million of cash, cash equivalents and marketable securities at 30 June 2026 and said on 13 August 2026 that its operating plan is funded into 2029. The second-quarter net loss was $24.1 million, according to the company's 10-Q.
• Pipeline breadth widened. On 1 October 2026 Aktis started the Phase 1b BActinium-2 trial of AKY-2519, a B7-H3-targeting miniprotein radioconjugate, in non-small cell lung cancer and other B7-H3-expressing solid tumors. A first Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer began in May 2026, with preliminary data expected in 2027.
• Analyst targets sit far above the price. Wedbush reiterated Outperform and a $35 target on 2 October 2026. Oppenheimer set $40 on 9 September 2026, Raymond James set $40 on 16 June 2026, and BMO Capital set $37 on 19 August 2026. A target cut before the data would weaken this point.

Bear case

• The $22 recovery level failed. The adjusted close was $19.43 on 25 September 2026, $17.74 on 8 October 2026 and $16.42 on 21 October 2026. A weekly close back above $22 would reverse this reading.
• Selling has persisted for months. The three-month change is -31.3%. The RSI(14) recovered from 18.0 on 8 October 2026 to 32.3 on 21 October 2026, yet the close still made a lower low.
• Insiders sold into the decline. A Form 4 filed 24 September 2026 reported a 23 September 2026 sale by chief medical officer Akos Czibere under a Rule 10b5-1 plan, a pre-arranged selling schedule. Further officer sales would add to the supply concern.
• No efficacy readout for months. NECTINIUM-2 data is guided for the first quarter of 2027, and AKY-2519 data for 2027. Benzinga's events page lists no scheduled corporate event after the Oppenheimer radiopharmaceutical summit on 17 September 2026.

Price setup

The adjusted close on 21 October 2026 was $16.42. That is below the $22.39 low of 30 July 2026 and well below the $25.78 close of 28 August 2026. Both levels now sit above the price, so no recent support level is intact.

The $16 round level is the next marker beneath the shares. A daily close below it would take the stock under every close since it fell through $22.

Crowding evidence points to selling rather than heavy buying. The RSI of 32.3 is no longer at the extreme of 18.0 seen on 8 October 2026, but the shares have not recovered. Insider selling under a 10b5-1 plan is on file. The third-quarter report has no confirmed date; MarketBeat's estimate is mid-November.

Catalysts, next 30 days

• ~12 November 2026 (est.): Third-quarter 2026 results and business update. The date is unconfirmed; Aktis reported the second quarter on 13 August 2026. The report tests the 2029 funding guidance and the first-quarter 2027 NECTINIUM-2 timetable.
• 31 March 2027: End of the guided window for preliminary NECTINIUM-2 data. This lies outside the 30-day window. The first efficacy readout for the lead program turns the case on it.

What would change the view

The case breaks if Aktis announces that preliminary NECTINIUM-2 data will arrive after the first quarter of 2027, or if the data shows weak efficacy. A daily close below $16 would also end it, because that is a round level beneath the $16.42 close of 21 October 2026 and under every close since the stock fell through $22.

The reading improves if the shares close a week above $22, or if the third-quarter report reaffirms the 2029 funding and first-quarter 2027 timing while the price holds above $16.

What it trades with

Aktis trades with other clinical-stage radiopharmaceutical developers and with small-cap biotech generally, since it has no revenue. Its price has moved on supply and sentiment rather than company news since the 13 August 2026 results. A sector-wide biotech sell-off or a rotation away from small-cap growth would add to the pressure independent of NECTINIUM-2.